EMA Authorised: Nyvepria (pegfilgrastim) — Pfizer Europe MA EEIG

View source ↗

Summary

EMA has authorised Nyvepria (pegfilgrastim) for use as a pegfilgrastim product. It is indicated to reduce the duration of chemotherapy-induced neutropenia in pa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Neutropenia

Drugs mentioned

• Nyvepria (pegfilgrastim)

Snippet

Status: Authorised. MAH: Pfizer Europe MA EEIG. Decision date: 20/01/2026